UK-369003

CAS No. 334827-98-4

UK-369003( Gisadenafil besylate )

Catalog No. M14135 CAS No. 334827-98-4

UK-369003 (Gisadenafil besylate) is a novel, potent, selective, orally bioavailable PDE5 inhibitor with IC50 of 1.23 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 224 Get Quote
50MG 799 Get Quote
100MG 1206 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    UK-369003
  • Note
    Research use only, not for human use.
  • Brief Description
    UK-369003 (Gisadenafil besylate) is a novel, potent, selective, orally bioavailable PDE5 inhibitor with IC50 of 1.23 nM.
  • Description
    UK-369003 (Gisadenafil besylate) is a novel, potent, selective, orally bioavailable PDE5 inhibitor with IC50 of 1.23 nM, displays 117-fold selectivity over PDE6; demonstrates efficacy in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).COPD Phase 2 Discontinued.
  • In Vitro
    Since some PDE5 inhibitors can also interact with PDE1 isotypes found within the cerebral vasculature, the specificity of Gisadenafil for PDE5 is confirmed. This is directly tested with recombinant PDE5A and PDE1A overexpressed in COS-7 cells. The IC50 of Gisadenafil for PDE5A is 3.6 nM. In contrast, the IC50 of Gisadenafil for PDE1A is 9.1 μM, an approximately 2500-fold difference in specificity.
  • In Vivo
    Gisadenafil (2 mg/kg; intraperitoneal injection; for 2 hours; male Tat-transgenic mice) treatment largely restores the normal increase in cortical flow following hypercapnia in Tat-tg mice (17.5% above baseline). Gisadenafil also restores the dilation of small (<25 μm) arterioles following hypercapnia, although it fails to restore full dilation of larger (>25 μm) vessels. Animal Model:Male Tat-transgenic (Tat-tg) mice (8 weeks old) exposed to hypercapnia Dosage:2 mg/kg Administration:Intraperitoneal injection; for 2 hours Result:Largely restored the normal increase in cortical flow following hypercapnia in Tat-tg mice (17.5% above baseline). Also restored the dilation of small (<25 μm) arterioles following hypercapnia.
  • Synonyms
    Gisadenafil besylate
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    PDE
  • Research Area
    Inflammation/Immunology
  • Indication
    COPD

Chemical Information

  • CAS Number
    334827-98-4
  • Formula Weight
    677.79
  • Molecular Formula
    C23H33N7O5S.C6H6O3S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (147.54 mM)
  • SMILES
    CCC1=C2C(=NN1CCOC)C(=O)NC(=N2)C3=C(N=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC.C1=CC=C(C=C1)S(=O)(=O)O
  • Chemical Name
    5-[2-Ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]-3-ethyl-2,6-dihydro-2-(2-methoxyethyl)-7H-pyrazolo[4,3-d]pyrimidin-7-one benzenesulfonate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Rawson DJ, et al. Bioorg Med Chem. 2012 Jan 1;20(1):498-509. 2. Martínez-Salamanca JI, et al. Eur Urol. 2011 Sep;60(3):527-35. 3. Watson KJ, et al. Drug Metab Dispos. 2011 Jul;39(7):1203-13.
molnova catalog
related products
  • WAY-313170

    WAY-313170 Inhibits hedgehog signaling and phosphodiesterase.

  • Resibufogenin

    Resibufogenin is a cytotoxic steroid isolated from the Chinese drug ChanSu. Resibufogenin can inhibit rectifier potassium current ( I K ) and transient potassium current ( I A ), it has pathological effects on central nervous system.

  • RPL-554

    RPL-554 (LS-193855, RPL554)?is a potent, orally available, dual PDE3/PDE4 inhibitor with IC50 of 0.4 nM and 1479 nM, respectively.